Cynthia Butitta
Directeur/Membre du Conseil chez UROGEN PHARMA LTD.
Fortune : 1 M $ au 30/04/2024
Profil
Ms. Cynthia M.
Butitta is an Independent Director at Century Therapeutics, Inc., an Independent Director at Olema Pharmaceuticals, Inc., an Independent Director at Autolus Ltd., an Independent Non-Executive Director at Autolus Therapeutics Plc, an Independent Director at UroGen Pharma Ltd.
and a Founder at Butitta Consulting Services LLC.
She is on the Board of Directors at Century Therapeutics, Inc., Olema Pharmaceuticals, Inc., Autolus Ltd., Autolus Therapeutics Plc and UroGen Pharma Ltd.
Ms. Butitta was previously employed as a Chief Operating Officer by Kite Pharma, Inc., a Chief Financial Officer & Senior Vice President by NextWave Pharmaceuticals, Inc., a Chief Operating & Financial Officer by Telik, Inc., a Partner by Altair Capital Associates LLC, a CFO, VP-Finance & Administration by Connective Therapeutics, Inc., and a Chief Financial Officer & VP-Administration by InSite Vision, Inc. She also served on the board at Century Therapeutics, Inc. /Old/ and Catalyst Semiconductor, Inc. She received her undergraduate degree from Edgewood College and an MBA from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/04/2024 | 83 876 ( 0,15% ) | 824 501 $ | 30/04/2024 | |
| 19/04/2024 | 98 936 ( 0,15% ) | 311 648 $ | 30/04/2024 | |
UROGEN PHARMA LTD.
-.--% | 07/09/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
AUTOLUS THERAPEUTICS PLC
-.--% | 29/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Cynthia Butitta
| Sociétés | Poste | Début |
|---|---|---|
| UROGEN PHARMA LTD. | Directeur/Membre du Conseil | 01/10/2017 |
| AUTOLUS THERAPEUTICS PLC | Directeur/Membre du Conseil | 01/03/2018 |
| OLEMA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/08/2020 |
| CENTURY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/02/2021 |
| Butitta Consulting Services LLC | Fondateur | 13/11/2009 |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Directeur/Membre du Conseil | 15/03/2018 |
Anciens postes connus de Cynthia Butitta
| Sociétés | Poste | Fin |
|---|---|---|
| KITE PHARMA INC | Directeur Financier/CFO | 16/05/2016 |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Directeur Financier/CFO | 01/12/2012 |
Telik, Inc.
 Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Directeur Financier/CFO | 01/12/2010 |
| ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Cynthia Butitta
| Edgewood College | Undergraduate Degree |
| University of Wisconsin | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| UROGEN PHARMA LTD. | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
InSite Vision, Inc.
 InSite Vision, Inc. Pharmaceuticals: MajorHealth Technology InSite Vision Inc. develops and markets ophthalmic pharmaceutical products that designs to treat a range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Its products include AzaSite, Besivance, AzaSite Plus, DexaSite, AzaSite Xtra, and ISV-10 and 303. The company was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA. | Health Technology |
Catalyst Semiconductor, Inc.
 Catalyst Semiconductor, Inc. SemiconductorsElectronic Technology Catalyst Semiconductor, Inc. engages in the design, development and sale of semiconductor products. Its products are used in communication, computing, industrial automation, consumer and automotive applications. It offers serial and parallel Flash/electrically erasable programmable read only memories (EEPROM), programmable micro-controller supervisory and voltage reference circuits and mixed signal devices. The company was founded in 1985 and is headquartered in Santa Clara, CA. | Electronic Technology |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Telik, Inc.
Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Health Technology |
NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Health Technology |
| Butitta Consulting Services LLC | |
| Altair Capital Associates LLC | |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Health Technology |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
